Search

India: Expert Opinion Indian Govt’s 1.3 Billion Healthcare Package to Boost Domestic API Manufacturing

| Editor: Ahlam Rais

The mega package is part of a turnaround strategy to reduce India’s dependence on China; states Prashant Khadayate, Pharma Analyst, Global Data. Three API manufacturing parks will also be set up in different parts of the country to enhance production.

Related Companies

The timing of the announcement was crucial as Indian pharma companies are facing potential supply disruptions due to the Covid-19 outbreak.
The timing of the announcement was crucial as Indian pharma companies are facing potential supply disruptions due to the Covid-19 outbreak.
(Source: Deposit Photos)

India – Following the news that India has approved a 1.3 billion healthcare package to boost the domestic manufacturing of active pharmaceutical ingredients (API); Prashant Khadayate, Pharma Analyst at Global Data, one of the leading data and analytics company, offers his view:

“The package, which is part of a turnaround strategy to reduce India’s dependence on China, will help boost the capabilities of domestic API manufacturers. The timing of the announcement was crucial as Indian pharma companies are facing potential supply disruptions due to the Covid-19 outbreak. Indian pharma manufacturers depend heavily for their supply of fine chemicals and drug intermediates on China.

“As part of the strategy, three API manufacturing parks will be set up in different parts of the country to further help in setting up API manufacturing units, and an incentive scheme will be implemented for the production of government identified API’s (53) by the manufacturers. For more information about the location of manufacturing facilities you can search Global Data Pharma Intelligence Center’s Contract Service Provider Database.

Specialist Book „Heat Transfer Technique“The comprehensive standard work „Heat Transfer Technique“ offers not only a detailed and well-founded presentation of the basics of heat transfer technique, but also shows the latest state of the art and the latest regulations in the use of organic fluids. Thematically, the book is rounded off with an overview of property data of organic heat transfer fluids as well as many use cases from practical experience.

“China is a key supplier of both Chemical API and chemical intermediates for the global pharmaceutical industry. The Covid-19 outbreak has the potential to disrupt the global supply chain for chemical APIs and impact pharmaceutical companies globally. It is important for the Indian pharma industry to protect itself and prepare to improve its intermediate and API manufacturing capabilities and supplies.

“This will also cement India’s position as a hub of API supply for global markets in the future. According to Global Data’s ‘Contract Small Molecule API Manufacturing Industry by the Numbers – 2019 Edition’ report, India has the largest number of dedicated contract manufacturing organisations (CMOs) with small molecule API manufacturing facilities approved by the US FDA or the EMA. With the government’s support, the Indian market will be less affected by changes in the supply chain.”

This article is protected by copyright. You want to use it for your own purpose? Contact us at support.vogel.de (ID: 46464105)